ABVX:EPA
Abivax SA
84,35 €
arrow_upward
+1,32%(+1,10) 1D
21-окт., 17:37:01 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
83,25 €
High
85,80 €
Low
82,25 €
Mkt. cap
7,38 млд
Avg. vol.
121,63 миң
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
83,25 €
High
85,80 €
Low
82,25 €
Mkt. cap
7,38 млд
Avg. vol.
121,63 миң
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
MarketBeat
·
2 мүнөт мурун
Nuveen NASDAQ 100 Dynamic Overwrite Fund (NASDAQ:QQQX) Shares Up 1.4% - Should You Buy?
TradingView
·
2 саат мурун
How Are Dow, S&P 500, Nasdaq Futures Trading After META, TSLA Earnings?
Kalkine Media
·
9 мүнөт мурун
Does a covered call ETF (QYLD) lose out when Nasdaq rallies?
CNBC
·
13 саат мурун
Why the stock market’s fragile calm faces a major test starting Friday
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com